Graham Capital Management, L.P. Mannkind Corp Transaction History

Graham Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.34 - $4.29 $187,985 - $241,454	-56,283 Reduced 61.35%	35,460 $129,000
Q3 2023 Nov 22, 2023	BUY	$3.91 - $5.45 $89,859 - $125,251	22,982 Added 33.42%	91,743 $378,000
Q2 2023 Aug 14, 2023	BUY	$3.72 - $4.79 $255,790 - $329,365	68,761 New	68,761 $279,000
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $140,327 - $250,696	-52,557 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $137,699 - $233,878	52,557 New	52,557 $193,000

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.